However, the treatment of IKZF1 deletion patients was intensified in MS2010, and the 5-year CIR presented no more significant difference in pediatric Ph− B-ALL (11.4% vs. 4.4%, P = 0.09). This evidence concerns the gene IKZF1 and acute lymphoblastic leukemia.